Editor of Patient Care Online.
Age and Aerobic Fitness Independently Linked to Atrial Arrhythmia Risk: Daily Dose
Your daily dose of the clinical news you may have missed.
Pooled Cohort Equations vs PREVENT: Statin Exposure Alters ASCVD Risk Predictions
The study found that although PREVENT-generated risk estimates were more consistent in a broad population, PCE estimates were more accurate in those taking statins.
Cervical Cancer Screening: What Primary Care Physicians Need to Know
PODCAST: Family physician Ada Stewart, MD, shares practical strategies for cervical cancer screening and patient communication.
Emerging Tau-Targeting Antibody for Alzheimer Disease Receives FDA Fast Track Designation
FDA grants Fast Track designation to etalanetug, a promising tau-targeting antibody for Alzheimer disease that could expand treatment options for the neurodegenerative disease.
Investigational IL-2 Pathway Agonist Rezpegaldesleukin Shows Promise in Phase 2b REZOLVE-AD Trial
The findings highlight rezpegaldesleukin's novel broad-based Treg mechanism, suggesting it may be a potent option with potential for disease modification in atopic dermatitis.
HHS Ties Acetaminophen Use During Pregnancy to Autism, Despite Widely Conflicting Evidence
The administration has initiated a nationwide public service campaign about the potential risks as professional societies quickly disputed the claims.
Semaglutide Shows Greater CVD Risk Reduction Than Tirzepatide in Adults With Obesity: Daily Dose
Expanding the Obesity Treatment Toolbox: The Promise of Dual-Action Medications
Michael Crotty, MD, an expert in obesity medicine, discusses GLP-1RAs in the context of weight loss, including the novel dual agonist survodutide.
Updated COVID-19 Vaccines Are Approved, But Population Restrictions Concern Experts
Seniors remain protected along with any adult or child with underlying risk factors for severe disease, but the healthy US population is left with a choice, so far.
Pilot Trial Challenges Routine Steroid Use After Pediatric Anaphylaxis ED Discharge
Corticosteroids following resolution of anaphylaxis should be chosen with clear, clinical rationale and reserved for select children, study authors concluded.
Urine-Based Cervical Cancer Screening Evaluated in World's Largest Study
The new study, based in China, will validate urine-based genetic methylation testing which concentrates trace amounts of HPV DNA by more than 10,000 times.
FDA Approves Guselkumab as First IL-23 Inhibitor With Fully Subcutaneous Induction Regimen for Ulcerative Colitis
FDA approves guselkumab as the first fully subcutaneous IL-23 inhibitor for ulcerative colitis, showing significant clinical benefits in trials.
GLP-1 RAs May Reduce Risk for Cancer in Adults with Obesity: Daily Dose
Cervical Cancer Screening in Primary Care: A Q&A with Family Physician Ada Stewart, MD
Explore essential insights on cervical cancer screening, patient engagement, and innovative self-collection methods this Gynecologic Cancer Awareness Month.
Elinzanetant Update: Phase 3 Findings Published in JAMA with PDUFA Date Set for October 26
If approved, the nonhormonal drug could offer an important new option for postmenopausal women seeking alternatives to hormone therapy.
FDA Approves Ruxolitinib for Pediatric Patients Aged 2-11 Years as First Topical JAK Inhibitor for the Age Group
Incyte announced the agency's decision, which was based on findings of significant reduction in atopic dermatitis signs and symptoms during the TRuE-AD3 clinical trial.
Emma Guttman-Yassky, MD, PhD, Outlines Phase 3 SHUTTLE Program with Rocatinlimab for Atopic Dermatitis
EADV 2025: Guttman-Yassky presented data from the phase 3 ROCKET-IGNITE trial and highlights its importance in the context of the global ROCKET development program.
Vaginal Estradiol Shows No Added Risk of Repeat Stroke in Women: Daily Dose
OX40 Inhibitor Rocatinlimab Shows Significant Response in Combination with Topical Therapy for AD
EADV 2025: Phase 3 ROCKET-SHUTTLE results showed the T-cell rebalancing therapy significantly improved AD signs and symptoms in treatment-experienced adults.
Cervical Cancer Screening in Primary Care: Family Physician Ada Stewart, MD, on Guidelines, Patient Hesitancy, and HPV Self-Collection
Ada Stewart, MD, reviews current guidelines, addresses patient hesitancy, and explains how HPV self-collection tests may expand screening options in primary care.
Temtokibart Shows Efficacy and Strong Biomarker Response in Phase 2b Trial for Atopic Dermatitis
The novel IL-22 blocker was associated with improvements in EASI as early as week 1 for lower doses and week 2 for the highest dose, compared with placebo.
Phase 3 Data Support Efficacy of Delgocitinib Cream in Adolescents With Chronic Hand Eczema; Pooled Analysis Confirms Safety in Adults
EADV 2025: New phase 3 data reveal delgocitinib cream's efficacy for chronic hand eczema in adolescents, confirming its safety profile in adults.
FDA Updates Albuterol/Budesonide Label to Include Evidence of Exacerbation Risk Reduction in Mild Asthma
The updated prescribing information includes phase 3b BATURA trial results showing a 46% reduction in severe exacerbations in mild asthma vs albuterol.
Tirzepatide Lowers A1C and BMI in Children and Adolescents with Type 2 Diabetes
In children aged 10 to <18 with T2D inadequately controlled on standard of care treatment, tirzepatide reduced HbA1c by an average of 2.2% and reduced BMI as well.
Nontraditional Causes of MI Found Common in Younger Adults, Especially in Women
Atypical causes of MI in women included spontaneous coronary artery dissection, which was 6 times more common in women than in men, a Mayo Clinic study found.
Alzheimer Disease: New Brain Targets and the New Drug Pipeline
Among 180+ active AD trials, 15 biological targets span traditional Aβ and tau proteins as well as new pathways in brain metabolism, neuroinflammation, and synaptic health.
Weekly Dose Podcast: Cervical Cancer Disparities, HPV Awareness Gaps, Depression Risk After Diagnosis, PharmFIT Preferences, and Semaglutide for MASH
This week’s podcast episode covers cervical cancer disparities, HPV awareness, depression risk, pharmacy CRC screening, and semaglutide approval for MASH.
Roflumilast Data Showcased Across Diverse Skin Conditions and Age Groups at EADV 2025
EADV 2025: Data will highlight the PDE4 inhibitor's efficacy across diverse populations and 3 common skin conditions: seborrheic dermatitis, atopic dermatitis, and psoriasis.
Investigational Oral GLP-1 RA, Orforglipron, Yields Dose-Dependent Weight Loss in Phase 3 Trial
EASD 2025. A new oral GLP-1 receptor agonist, orforglipron, shows promise for significant weight loss and improved cardiometabolic health in adults with obesity.
Semaglutide Quells "Food Noise," Improves Mental Health Among Adults on Treatment for Obesity and Overweight
EASD 2025: After initiating treatment with semaglutide, the number of people who reported experiencing constant thoughts about food throughout the day declined by 46%.
